Kalb Michael Wayne sold (to issuer) $430K of CPRX
Kalb Michael Wayne (Chief Financial Officer) sold (to issuer) 13,665 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($0.43M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s sale to the issuer: 13,665 shares at $31.50, totaling $430,447.50, leaving 0 shares after the transaction.
Market read
Traders may note insider selling activity, but there is no new fundamental Catalyst Pharmaceuticals catalyst in the text.
What to watch
The Form 4 states no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty, but the filing still lacks any accompanying company-specific news.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals (CPRX).
Ticker impact
Catalyst Pharmaceuticals CFO Kalb Michael Wayne sold 13,665 shares to the issuer at $31.50 on 2026-07-15, per a fresh Form 4 filing.
Likely limited near-term impact; any effect would be sentiment-driven and short-lived.
The filing discloses a specific insider transaction size and price, but provides no new operational, regulatory, or financial catalyst.
Market effects
No clear read-across to the broader biotech sector from a single CFO sale.
No material regional market implications indicated.
No global relevance beyond Catalyst Pharmaceuticals-specific sentiment.
Counterpoint
Insider sales to the issuer can be administrative or liquidity-related and may not reflect negative expectations.
Key entities
- issuerCatalyst Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderKalb Michael Wayne
Chief Financial Officer who sold shares to the issuer.